Literatur (Weitere Literatur beim Verfasser)
-
1
Alsalameh S, Burian M, Mahr G, Woodcock B G, Geisslinger G.
Review article: the pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor.
Aliment Pharmacol Ther.
2003;
17
489-501
-
2
Bombardier C, Laine L, Reicin A. et al for the VIGOR Study Group .
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
N Engl J Med.
2000;
343
1520-1528
-
3
Farkouh M E, Korshner H, Harrington R A. et al .
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Lancet.
2004;
364
675-684
-
4 FDA CLASS Advisory Committee .CLASS Advisory Committee briefing document. Available at http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_01_searle.pdf 2001
-
5
FitzGerald G A.
COX-2 and beyond: approaches to prostaglandin inhibition in human disease.
Nature Drug Disc.
2003;
2
879-890
-
6
FitzGerald G A.
Coxibs and cardiovascular disease.
N Engl J Med.
2004;
351
1709-1711
-
7
John S, Schmieder R E.
Beeinflussen COX-2-Inhibitoren das kardiovaskuläre Risiko?.
Dtsch Med Wochenschr.
2002;
127
156-159
-
8
Jüni P, Rutjes A WS, Dieppe P A.
Are selective COX-2 inhibitors superior to traditional non-steroidal antiinflammatory drugs?.
Br Med J.
2002;
324
1287-1288
-
9
Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe P A, Egger M.
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
Lancet.
2004;
364
4999-5007
-
10
Mukherjee D.
Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.
Biochem Pharmacol.
2002;
63
817-821
-
11
Schnitzer T J, Burmester G R, Mysler E. et al .
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Lancet.
2004;
364
665-674
-
12 Schwabe U. Paffrath D Arzneiverordnungsreport 2004,. Springer Verlag Berlin-Heidelberg-New York ISBN 3-540-21359-7
-
13
Zimmermann K C, Sarbia M, Schrör K, Weber A -A.
Constitutive cyclooxygenase-2-expression in healthy human and rabbit gastric mucosa.
Mol Pharmacol.
1998;
54
536-540
Prof. Dr. Karsten Schrör
Institut für Pharmakologie und Klinische Pharmakologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf
Universitätsstraße 1, Geb. 22.21
40225 Düsseldorf
Phone: 0211/8112500
Fax: 0211/8114781
Email: kschroer@uni-duesseldorf.de
